跳轉至內容
Merck
  • Endophthalmitis caused by streptococcal species: clinical settings, microbiology, management, and outcomes.

Endophthalmitis caused by streptococcal species: clinical settings, microbiology, management, and outcomes.

American journal of ophthalmology (2014-01-15)
Ajay E Kuriyan, Kathleen D Weiss, Harry W Flynn, William E Smiddy, Audina M Berrocal, Thomas A Albini, Darlene Miller
摘要

To report the clinical settings, antibiotic susceptibilities, and outcomes of endophthalmitis caused by Streptococcus species. Retrospective, observational case series. Single-center study evaluating all patients with culture-positive endophthalmitis caused by Streptococcus species between January 1, 2000, and December 31, 2011. Study criteria were met by 63 patients. The most common clinical settings were bleb associated (n = 17; 27%), after intravitreal injection (n = 16; 25%), and after cataract surgery (n = 13; 21%). The isolates were Streptococcus viridans (n = 47; 71%), Streptococcus pneumoniae (n = 13; 21%), and β-hemolytic Streptococci (n = 5; 8%). Sixty (95%) of 63 isolates were susceptible to vancomycin, 47 (98%) of 48 isolates were susceptible to ceftriaxone (third-generation cephalosporin), and 57 (93%) of 61 isolates were susceptible to levofloxacin (third-generation fluoroquinolone). Between the first and second half of the study, the minimal inhibitory concentration of antibiotics required to inhibit 90% of isolates increased by 1.5-fold for ceftriaxone and 2-fold for levofloxacin and remained the same for vancomycin. Initial treatment was vitreous tap (49; 78%) or pars plana vitrectomy (14; 22%); all received intravitreal antibiotics. Visual acuity outcomes were variable: best-corrected visual acuity was 20/400 or better in 16 (25%) patients and worse than 20/400 in 47 (75%) patients. Evisceration or enucleation was performed in 16 (25%) patients. Streptococcus isolates generally had high susceptibility rates to commonly used antibiotics. Higher antibiotic minimal inhibitory concentrations were required to inhibit 90% of isolates in vitro in the second half of the study period compared with the first half. Despite prompt treatment, most patients had poor outcomes.

材料
產品編號
品牌
產品描述

Sigma-Aldrich
万古霉素 盐酸盐 来源于东方链霉菌, ≥900 μg per mg (as vancomycin base)
Sigma-Aldrich
万古霉素 盐酸盐 来源于东方链霉菌, ≥85% (Vancomycin B)
Sigma-Aldrich
万古霉素 盐酸盐 来源于东方链霉菌, BioReagent, suitable for plant cell culture
Sigma-Aldrich
阿米卡星 水合物, aminoglycoside antibiotic
Sigma-Aldrich
阿米卡星 二硫酸盐, potency: 674-786 μg per mg (as amikacin base)
USP
Ceftazidime pentahydrate, United States Pharmacopeia (USP) Reference Standard
Ceftazidime, European Pharmacopoeia (EP) Reference Standard
Vancomycin 盐酸盐, European Pharmacopoeia (EP) Reference Standard
Millipore
万古霉素添加剂, suitable for microbiology
Sigma-Aldrich
万古霉素 盐酸盐 来源于东方链霉菌, meets USP testing specifications
阿米卡星, European Pharmacopoeia (EP) Reference Standard
阿米卡星 硫酸酯, European Pharmacopoeia (EP) Reference Standard
Ceftazidime for peak identification, European Pharmacopoeia (EP) Reference Standard